Case Report: Clinical phenotypes and recombinant human growth hormone therapeutic exploration for a patient with Takenouchi-Kosaki syndrome harboring the CDC42 p.Arg68Gln variant
Xiao-xiao Lin, Yuan-yuan Song, Jia-cheng Xue, Hua Liu · 2026
Read Case Report: Clinical phenotypes and recombinant human growth hormone therapeutic exploration for a patient with Takenouchi-Kosaki syndrome harboring the CDC42 p.Arg68Gln variant by Xiao-xiao Lin, Yuan-yuan Song, Jia-cheng Xue, Hua Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13576681.txt.
Description
Xiao-xiao Lin and colleagues report growth hormone treatment in a child with Takenouchi-Kosaki syndrome. Their 2026 case follows a girl with an ultra-rare CDC42 variant. The syndrome brings severe short stature and distinct facial traits. Low platelet counts and progressive hearing loss marked her course. Immune gaps, including low white cells, were also found.
Gene testing confirmed the rare variant as the main cause. A second gene's variants were judged unlikely to drive hearing loss. Off-label growth hormone therapy targeted her short stature. Six months of follow-up showed favorable catch-up growth. The team reviewed past reports to place the variant. Such cases add scarce data on ultra-rare disease care. Hormone use in this syndrome gains a first careful record.
Catalog record
| CREATOR | Xiao-xiao Lin, Yuan-yuan Song, Jia-cheng Xue, Hua Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |